RVPH
NASDAQReviva Pharmaceuticals Holdings Inc.
Price$0.36-3.88 (-91.61%)
2026-03-052026-06-08
News · 26 weeks40-87%
2025-12-142026-06-07
Mix2690d
- Other11(42%)
- SEC Filings10(38%)
- Offering3(12%)
- Insider2(8%)
Latest news
25 items- PRReviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company ShowcaseCUPERTINO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.'s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026. Fireside Chat Details: Time: 2:40-3:00 PM ETDate: Wednesday, May 20, 2026 Investors can register for the conference and vie
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13G/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- SECSEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- SECSEC Form 10-Q filed by Reviva Pharmaceuticals Holdings Inc.10-Q - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECReviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- PRReviva Reports First Quarter 2026 Financial Results and Recent Business Highlights- Composition of matter provisional patent application filed for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 - - FDA feedback on use of new form of brilaroxazine in the RECOVER-2 trial and future NDA expected in mid-2026 -- Initiation of patient enrollment in RECOVER-2 registrational Phase 3 trial expected Q3 2026 - CUPERTINO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, to
- SECReviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- PRReviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric IndicationsCUPERTINO, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD, Founder, President, and CEO of Reviva, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James Molloy on Monday, April 27, 2026 at 11:00 AM ET. The fireside chat will highlight the recent developments from Reviva's clinical stage drug candidate brilaroxazine and upcoming clinical, regulatory
- SECReviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- PRReviva Announces Letter to ShareholdersCUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D. The full text of the letter follows. Dear Fellow Shareholders: The past year has been an important and challenging period for Reviva Pharmaceuticals. We have made difficult but necessary decisions to strengthen our capital position, preserve strategic flexibilit
- SECSEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- SECSEC Form S-8 filed by Reviva Pharmaceuticals Holdings Inc.S-8 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECReviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form 10-K filed by Reviva Pharmaceuticals Holdings Inc.10-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- PRReviva Reports Full Year 2025 Financial Results and Recent Business Highlights- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – - Current data package highlights well-tolerated long-term safety profile, broad-spectrum clinical activity, and favorable adherence for once daily brilaroxazine up to one year - - Initiation of RECOVER-2 registrational trial planned in mid-2026 - CUPERTINO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (C
- SECSEC Form SCHEDULE 13G filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13G - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Reviva Pharmaceuticals Holdings Inc.SCHEDULE 13D/A - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Subject)
- PRReviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public OfferingCUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the closing on March 20, 2026 of its previously announced public offering with healthcare focused institutional investors for the purchase and sale of 6,666,667 shares of its common stock (or common stock equivalents in lieu thereof) together with Series G warrants to purchase up to 6,666,667 shares of common stock (the "Series G Warrants") and Series H warr
- INSIDERSEC Form 4 filed by Prabhu Narayan4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
- INSIDERSEC Form 4 filed by Bhat Laxminarayan4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)
- SECReviva Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- SECSEC Form 424B5 filed by Reviva Pharmaceuticals Holdings Inc.424B5 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Filer)
- PRReviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingCUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with healthcare focused institutional investors for the purchase and sale of 6,666,667 shares of its common stock (or common stock equivalents in lieu thereof) together with Series G warrants to purchase up to 6,666,667 shares of common stock (the "Series G Warrants") and Series H warrants to purchase u
- PRReviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingCUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the of
RVPH FAQ
7 questionsWhat does Reviva Pharmaceuticals Holdings Inc. do?
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Its lead product candidate is RP5063 that has completed Phase II clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials for treating bipolar disorder, major depressive disorder, behavioral and psychotic symptoms, dementia or Alzheimer's...Where does RVPH stock trade?
Reviva Pharmaceuticals Holdings Inc. (RVPH) is listed on NASDAQ.What sector and industry is RVPH in?
Reviva Pharmaceuticals Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Reviva Pharmaceuticals Holdings Inc. go public?
Reviva Pharmaceuticals Holdings Inc. (RVPH) completed its IPO in 2020.What are analysts saying about RVPH?
Reviva Pharmaceuticals Holdings Inc. has had 6 recent analyst actions on file. The most recent action was from D. Boral Capital: Hold on 2026-03-05.What companies are similar to RVPH?
Notable peers in the same industry include MIRM (Mirum Pharmaceuticals Inc.), KNSA (Kiniksa Pharmaceuticals International plc), SUPN (Supernus Pharmaceuticals Inc.), ADMS (Adamas Pharmaceuticals, Inc.), ACRX (AcelRx Pharmaceuticals Inc.). Compare RVPH side-by-side with any of them on Quantisnow.How can I track RVPH on Quantisnow?
Quantisnow aggregates Reviva Pharmaceuticals Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RVPH to receive live email and push alerts on every new disclosure.